Shares of healthcare services companies are trading lower amid sympathy with HCA Healthcare after that company lowered its FY26 GAAP EPS guidance.

Can Pediatrix Sustain Growth Despite Lower Patient Volumes?

Pediatrix Medical Group (MD) reported 4% YoY revenue growth to $487.8 million in Q2 2026, driven by improved reimbursement and higher patient acuity, offsetting a 2.1% decline in patient volumes. The company reaffirmed its 2026 adjusted EBITDA guidance of $280-$300 million, though volume trends and easing collection benefits remain key risks.

This Baidu Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and price targets on Benzinga's analyst page.

Jefferies Downgrades Pediatrix Medical Group to Hold, Raises Price Target to $28

Jefferies analyst Jack Slevin downgrades Pediatrix Medical Group (NYSE:MD) from Buy to Hold and raises the price target from $27 to $28.

UBS Maintains Neutral on Pediatrix Medical Group, Raises Price Target to $28

UBS analyst A.J. Rice maintains Pediatrix Medical Group (NYSE:MD) with a Neutral and raises the price target from $25 to $28.

TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

TD Cowen analyst Ryan Langston reiterates Surgery Partners (NASDAQ:SGRY) with a Buy and maintains $19 price target.

Surgery Partners Updates FY2026 Revenue Guidance To $3.08B-$3.18B, Adjusted EBITDA To At Least $489M Following Idaho Falls Sale